Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections

Nina M. Clark; Shellee A. Grim; Joseph P. Lynch III

doi:10.1055/s-0035-1562902

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2015; 36(05): 767-785
DOI: 10.1055/s-0035-1562902

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections

Authors

Nina M. Clark

¹Division of Infectious Diseases, Department of Medicine, Loyola University Medical Center, Maywood, Illinois
Shellee A. Grim

¹Division of Infectious Diseases, Department of Medicine, Loyola University Medical Center, Maywood, Illinois

²Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois
Joseph P. Lynch III

³Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, The David Geffen School of Medicine at UCLA, Los Angeles, California

Abstract

Posaconazole, a fluorinated triazole antifungal drug, is approved by the U.S. Food and Drug Administration (FDA) for (1) prophylaxis against Aspergillus and Candida infections in immunocompromised patients at high risk for these infections and (2) oropharyngeal candidiasis (OPC), including cases refractory to fluconazole and/or itraconazole. The European Medicines Agency (EMA) has approved posaconazole for (1) treatment of aspergillosis, fusariosis, chromoblastomycosis, and coccidioidomycosis in patients who are refractory to or intolerant of other azoles or amphotericin B; (2) first-line therapy for OPC for severe disease or in those unlikely to respond to topical therapy; and (3) prophylaxis of invasive fungal infections in high-risk hematologic patients and stem cell transplant recipients. In addition to approved indications, posaconazole has been used with success as salvage therapy for invasive mold infections and endemic mycoses in patients who are refractory to or intolerant of other antifungal agents, and as prophylaxis or salvage therapy in children, for whom indications are more limited owing to a paucity of data. Posaconazole has potent in vitro activity against a broad range of fungi and molds, including Aspergillus, Candida, Cryptococcus, filamentous fungi, and endemic mycoses including coccidioidomycosis, histoplasmosis, and blastomycosis. Importantly, posaconazole is much more active than other azoles against many Mucorales species and the combination of posaconazole with other antifungal agents may be synergistic. Hence, posaconazole is a potential candidate as a single or combination agent for difficult-to-treat fungal infections. Posaconazole has an excellent safety profile; to date, serious side effects are rare, even with prolonged use. However, newer posaconazole formulations achieve higher blood levels and it remains to be seen whether this may lead to an increase in the rate of adverse effects. Currently, posaconazole is used predominantly for prophylaxis and salvage therapy of fungal infections in adults. Indications for use as initial therapy of fungal infections and for broader use in children will depend on the accrual of additional clinical data.

Keywords

posaconazole - fungal infections - mold infections - azoles - mucormycosis - Aspergillus

Full Text

References

References
1 Noxafil [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2014
2 Cornely OA, Maertens J, Winston DJ , et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356 (4) 348-359
3 Ullmann AJ, Lipton JH, Vesole DH , et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356 (4) 335-347
4 Vazquez JA, Skiest DJ, Nieto L , et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006; 42 (8) 1179-1186
5 Skiest DJ, Vazquez JA, Anstead GM , et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44 (4) 607-614
6 Noxafil: EPAR–Summary for the public. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000610/WC500037785.pdf . Accessed November 26, 2014
7 Walsh TJ, Raad I, Patterson TF , et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44 (1) 2-12
8 Heinz WJ, Egerer G, Lellek H, Boehme A, Greiner J. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. Mycoses 2013; 56 (3) 304-310
9 van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42 (7) e61-e65
10 Greenberg RN, Mullane K, van Burik JA , et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50 (1) 126-133
11 Proia LA, Harnisch DO. Successful use of posaconazole for treatment of blastomycosis. Antimicrob Agents Chemother 2012; 56 (7) 4029
12 Kim MM, Vikram HR, Kusne S, Seville MT, Blair JE. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis 2011; 53 (11) 1060-1066
13 Schein R, Homans J, Larsen RA, Neely M. Posaconazole for chronic refractory coccidioidal meningitis. Clin Infect Dis 2011; 53 (12) 1252-1254
14 Restrepo A, Tobón A, Clark B , et al. Salvage treatment of histoplasmosis with posaconazole. J Infect 2007; 54 (4) 319-327
15 Döring M, Blume O, Haufe S , et al. Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis 2014; 33 (4) 629-638
16 Döring M, Müller C, Johann PD , et al. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis 2012; 12: 263
17 Cesaro S, Milano GM, Aversa F. Retrospective survey on the off-label use of posaconazole in pediatric hematology patients. Eur J Clin Microbiol Infect Dis 2011; 30 (4) 595-596
18 Lehrnbecher T, Attarbaschi A, Duerken M , et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis 2010; 29 (8) 1043-1045
19 Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med 2008; 29 (2) 198-210
20 Pasqualotto AC, Thiele KO, Goldani LZ. Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole. Curr Opin Investig Drugs 2010; 11 (2) 165-174
21 Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005; 5 (12) 775-785
22 Katragkou A, Tsikopoulou F, Roilides E, Zaoutis TE. Posaconazole: when and how? The clinician's view. Mycoses 2012; 55 (2) 110-122
23 Keating GM. Posaconazole. Drugs 2005; 65 (11) 1553-1567 , discussion 1568–1569
24 Kauffman CA, Malani AN, Easley C, Kirkpatrick P. Posaconazole. Nat Rev Drug Discov 2007; 6 (3) 183-184
25 Ma LJ, Ibrahim AS, Skory C , et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet 2009; 5 (7) e1000549
26 Schwartze VU, Winter S, Shelest E , et al. Gene expansion shapes genome architecture in the human pathogen Lichtheimia corymbifera: an evolutionary genomics analysis in the ancient terrestrial Mucorales (Mucoromycotina). PLoS Genet 2014; 10 (8) e1004496
27 Lewis RE, Ben-Ami R, Best L, Albert N, Walsh TJ, Kontoyiannis DP. Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis. J Infect Dis 2013; 207 (5) 834-841
28 Castanheira M, Messer SA, Jones RN, Farrell DJ, Pfaller MA. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. Int J Antimicrob Agents 2014; 44 (4) 320-326
29 Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012; 50 (9) 2846-2856
30 Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013; 51 (8) 2571-2581
31 Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother 2011; 55 (2) 561-566
32 Sabatelli F, Patel R, Mann PA , et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50 (6) 2009-2015
33 Ramani R, Chaturvedi V. Antifungal susceptibility profiles of Coccidioides immitis and Coccidioides posadasii from endemic and non-endemic areas. Mycopathologia 2007; 163 (6) 315-319
34 Wheat LJ, Connolly P, Smedema M , et al. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother 2006; 57 (6) 1235-1239
35 Sugar AM, Liu XP. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 1996; 40 (5) 1314-1316
36 Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41 (8) 3623-3626
37 Pfaller MA, Messer SA, Hollis RJ, Jones RN ; SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46 (4) 1032-1037
38 Drogari-Apiranthitou M, Mantopoulou FD, Skiada A , et al. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. J Antimicrob Chemother 2012; 67 (8) 1937-1940
39 Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of Zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007; 51 (7) 2587-2590
40 de Macedo-Silva ST, Urbina JA, de Souza W, Rodrigues JC. In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis. PLoS ONE 2013; 8 (12) e83247
41 Paniz Mondolfi AE, Stavropoulos C, Gelanew T , et al. Successful treatment of Old World cutaneous leishmaniasis caused by Leishmania infantum with posaconazole. Antimicrob Agents Chemother 2011; 55 (4) 1774-1776
42 Molina I, Gómez i Prat J, Salvador F , et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med 2014; 370 (20) 1899-1908
43 Roberts CW, McLeod R, Rice DW, Ginger M, Chance ML, Goad LJ. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol 2003; 126 (2) 129-142
44 Arendrup MC, Cuenca-Estrella M, Donnelly JP, Hope W, Lass-FlÖrl C, Rodriguez-Tudela JL. European Committee on Antimicrobial Susceptibility Testing - Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). Clin Microbiol Infect 17 (11) E16-7
45 Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol 2008; 46 (2) 551-559
46 Pfaller MA, Diekema DJ. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J Invasive Fungal Infect 2007; 1: 74
47 Barchiesi F, Spreghini E, Schimizzi AM , et al. Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. Antimicrob Agents Chemother 2004; 48 (9) 3312-3316
48 Ballester F, Pastor FJ, Guarro J. In vitro activities of combinations of amphotericin B, posaconazole and four other agents against Rhizopus. J Antimicrob Chemother 2008; 61 (3) 755-757
49 Guembe M, Guinea J, Peláez T, Torres-Narbona M, Bouza E. Synergistic effect of posaconazole and caspofungin against clinical Zygomycetes. Antimicrob Agents Chemother 2007; 51 (9) 3457-3458
50 Perkhofer S, Locher M, Cuenca-Estrella M , et al. Posaconazole enhances the activity of amphotericin B against hyphae of Zygomycetes in vitro. Antimicrob Agents Chemother 2008; 52 (7) 2636-2638
51 Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus . Med Mycol 2008; 46 (6) 567-573
52 Najvar LK, Cacciapuoti A, Hernandez S , et al. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories. Antimicrob Agents Chemother 2004; 48 (3) 758-764
53 Lepak AJ, Marchillo K, VanHecker J, Andes DR. Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates. Antimicrob Agents Chemother 2013; 57 (11) 5438-5447
54 Walsh TJ, Anaissie EJ, Denning DW , et al; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46 (3) 327-360
55 Maertens J, Marchetti O, Herbrecht R , et al; Third European Conference on Infections in Leukemia. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant 2011; 46 (5) 709-718
56 Skiada A, Lanternier F, Groll AH , et al; European Conference on Infections in Leukemia. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 2013; 98 (4) 492-504
57 Ananda-Rajah MR, Grigg A, Downey MT , et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica 2012; 97 (3) 459-463
58 Rogers TR, Slavin MA, Donnelly JP. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?. Br J Haematol 2011; 153 (6) 681-697
59 Vehreschild JJ, Rüping MJ, Wisplinghoff H , et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother 2010; 65 (7) 1466-1471
60 Girmenia C, Frustaci AM, Gentile G , et al. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica 2012; 97 (4) 560-567
61 Kung HC, Johnson MD, Drew RH, Saha-Chaudhuri P, Perfect JR. Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study. Cancer Med 2014; 3 (3) 667-673
62 Gomes MZ, Mulanovich VE, Jiang Y, Lewis RE, Kontoyiannis DP. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011. Antimicrob Agents Chemother 2014; 58 (2) 865-873
63 Pechlivanoglou P, Le HH, Daenen S, Snowden JA, Postma MJ. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review. J Antimicrob Chemother 2014; 69 (1) 1-11
64 Gomes MZ, Jiang Y, Mulanovich VE, Lewis RE, Kontoyiannis DP. Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia. Antimicrob Agents Chemother 2014; 58 (5) 2775-2780
65 Denning DW, Bowyer P. Voriconazole resistance in Aspergillus fumigatus: should we be concerned?. Clin Infect Dis 2013; 57 (4) 521-523
66 Freifeld AG, Bow EJ, Sepkowitz KA , et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52 (4) e56-e93
67 Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007; 45 (12) 1610-1617
68 Baddley JW, Andes DR, Marr KA , et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50 (12) 1559-1567
69 Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18 (1) 44-69
70 Thompson III GR, Patterson TF. Pulmonary aspergillosis: recent advances. Semin Respir Crit Care Med 2011; 32 (6) 673-681
71 Herbrecht R, Denning DW, Patterson TF , et al; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347 (6) 408-415
72 Kepenekli E, Soysal A, Kuzdan C, Ermerak NO, Yüksel M, Bakır M. Refractory invasive aspergillosis controlled with posaconazole and pulmonary surgery in a patient with chronic granulomatous disease: case report. Ital J Pediatr 2014; 40: 2
73 Raad II, Hanna HA, Boktour M , et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 2008; 22 (3) 496-503
74 Alexander BD, Perfect JR, Daly JS , et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 2008; 86 (6) 791-796
75 Felton TW, Baxter C, Moore CB, Roberts SA, Hope WW, Denning DW. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis 2010; 51 (12) 1383-1391
76 Chishimba L, Niven RM, Cooley J, Denning DW. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J Asthma 2012; 49 (4) 423-433
77 Cornely OA, Bassetti M, Calandra T , et al; ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18 (Suppl. 07) 19-37
78 Pappas PG, Kauffman CA, Andes D , et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48 (5) 503-535
79 Kett DH, Azoulay E, Echeverria PM, Vincent JL ; Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011; 39 (4) 665-670
80 Ruhnke M, Rickerts V, Cornely OA , et al; German Speaking Mycological Society; Paul-Ehrlich-Society for Chemotherapy. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 2011; 54 (4) 279-310
81 Colombo AL, Guimarães T, Camargo LF , et al. Brazilian guidelines for the management of candidiasis - a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical. Braz J Infect Dis 2013; 17 (3) 283-312
82 Firinu D, Massidda O, Lorrai MM , et al. Successful treatment of chronic mucocutaneous candidiasis caused by azole-resistant Candida albicans with posaconazole. Clin Dev Immunol 2011; 2011: 283239
83 Perfect JR, Dismukes WE, Dromer F , et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50 (3) 291-322
84 Espinel-Ingroff A, Aller AI, Canton E , et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 2012; 56 (11) 5898-5906
85 Lockhart SR, Iqbal N, Bolden CB , et al; Cryptococcus gattii PNW Public Health Working Group. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. Diagn Microbiol Infect Dis 2012; 73 (2) 144-148
86 Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. Diagn Microbiol Infect Dis 2011; 71 (3) 252-259
87 Cleveland KO, Gelfand MS, Rao V. Posaconazole as successful treatment for fungemia due to Cryptococcus albidus in a liver transplant recipient. QJM 2013; 106 (4) 361-362
88 Esposito V, Viglietti R, Gargiulo M , et al. Successful treatment of Cryptococcal meningitis with a combination of liposomal amphotericin B, flucytosine and posaconazole: two case reports. In Vivo 2009; 23 (3) 465-468
89 Day SR, Weiss DB, Hazen KC, Moore CC. Successful treatment of osseous blastomycosis without pulmonary or disseminated disease and review of the literature. Diagn Microbiol Infect Dis 2014; 79 (2) 242-244
90 McKinsey DS, McKinsey JP. Pulmonary histoplasmosis. Semin Respir Crit Care Med 2011; 32 (6) 735-744
91 Gonçalves D, Ferraz C, Vaz L. Posaconazole as rescue therapy in African histoplasmosis. Braz J Infect Dis 2013; 17 (1) 102-105
92 Catanzaro A, Cloud GA, Stevens DA , et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007; 45 (5) 562-568
93 Anstead GM, Corcoran G, Lewis J, Berg D, Graybill JR. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 2005; 40 (12) 1770-1776
94 Stevens DA, Rendon A, Gaona-Flores V , et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007; 132 (3) 952-958
95 Dismukes WE, Bradsher Jr RW, Cloud GC , et al; NIAID Mycoses Study Group. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992; 93 (5) 489-497
96 Chapman SW, Dismukes WE, Proia LA , et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008; 46 (12) 1801-1812
97 Bradsher RW. Blastomycosis. Clin Infect Dis 1992; 14 (Suppl. 01) S82-S90
98 Borgia SM, Fuller JD, Sarabia A, El-Helou P. Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen. Med Mycol 2006; 44 (7) 659-664
99 Bakleh M, Aksamit AJ, Tleyjeh IM, Marshall WF. Successful treatment of cerebral blastomycosis with voriconazole. Clin Infect Dis 2005; 40 (9) e69-e71
100 Panicker J, Walsh T, Kamani N. Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole. Pediatr Infect Dis J 2006; 25 (4) 377-379
101 Bariola JR, Perry P, Pappas PG , et al. Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis 2010; 50 (6) 797-804
102 Grim SA, Proia L, Miller R , et al. A multicenter study of histoplasmosis and blastomycosis after solid organ transplantation. Transpl Infect Dis 2012; 14 (1) 17-23
103 Galgiani JN, Ampel NM, Blair JE , et al; Infectious Diseases Society of America. Coccidioidomycosis. Clin Infect Dis 2005; 41 (9) 1217-1223
104 Proia LA, Tenorio AR. Successful use of voriconazole for treatment of Coccidioides meningitis . Antimicrob Agents Chemother 2004; 48 (6) 2341
105 Freifeld A, Proia L, Andes D , et al. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 2009; 53 (4) 1648-1651
106 Levy ER, McCarty JM, Shane AL, Weintrub PS. Treatment of pediatric refractory coccidioidomycosis with combination voriconazole and caspofungin: a retrospective case series. Clin Infect Dis 2013; 56 (11) 1573-1578
107 Prabhu RM, Bonnell M, Currier BL, Orenstein R. Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole. Clin Infect Dis 2004; 39 (7) e74-e77
108 Limper AH, Knox KS, Sarosi GA , et al; American Thoracic Society Fungal Working Group. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183 (1) 96-128
109 Wheat LJ, Freifeld AG, Kleiman MB , et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45 (7) 807-825
110 Connolly P, Wheat J, Schnizlein-Bick C , et al. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother 1999; 43 (2) 322-328
111 Connolly P, Wheat LJ, Schnizlein-Bick C , et al. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob Agents Chemother 2000; 44 (10) 2604-2608
112 Freifeld AG, Wheat LJ, Kaul DR. Histoplasmosis in solid organ transplant recipients: early diagnosis and treatment. Curr Opin Organ Transplant 2009; 14 (6) 601-605
113 Dhawan J, Verma P, Sharma A, Ramam M, Kabra SK, Gupta S. Disseminated cutaneous histoplasmosis in an immunocompetent child, relapsed with itraconazole, successfully treated with voriconazole. Pediatr Dermatol 2010; 27 (5) 549-551
114 Srinivasan J, Ooi WW. Successful treatment of histoplasmosis brain abscess with voriconazole. Arch Neurol 2008; 65 (5) 666-667
115 Clark B, Foster R, Tunbridge A, Green S. A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole. J Infect 2005; 51 (3) e177-e180
116 Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis 2012; 54 (Suppl. 01) S8-S15
117 Rüping MJ, Heinz WJ, Kindo AJ , et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010; 65 (2) 296-302
118 Skiada A, Pagano L, Groll A , et al; European Confederation of Medical Mycology Working Group on Zygomycosis. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17 (12) 1859-1867
119 Cornely OA, Arikan-Akdagli S, Dannaoui E , et al; European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group; European Confederation of Medical Mycology. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014; 20 (Suppl. 03) 5-26
120 Roden MM, Zaoutis TE, Buchanan WL , et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41 (5) 634-653
121 Doligalski CT, Benedict K, Cleveland AA , et al. Epidemiology of invasive mold infections in lung transplant recipients. Am J Transplant 2014; 14 (6) 1328-1333
122 Hamilos G, Samonis G, Kontoyiannis DP. Pulmonary mucormycosis. Semin Respir Crit Care Med 2011; 32 (6) 693-702
123 Mitchell TA, Hardin MO, Murray CK , et al. Mucormycosis attributed mortality: a seven-year review of surgical and medical management. Burns 2014; 40 (8) 1689-1695
124 Pyrgos V, Shoham S, Walsh TJ. Pulmonary zygomycosis. Semin Respir Crit Care Med 2008; 29 (2) 111-120
125 Lanternier F, Dannaoui E, Morizot G , et al; French Mycosis Study Group. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis 2012; 54 (Suppl. 01) S35-S43
126 Vehreschild JJ, Birtel A, Vehreschild MJ , et al. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol 2013; 39 (3) 310-324
127 Bitar D, Van Cauteren D, Lanternier F , et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009; 15 (9) 1395-1401
128 Bitar D, Lortholary O, Le Strat Y , et al. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis 2014; 20 (7) 1149-1155
129 Saegeman V, Maertens J, Meersseman W, Spriet I, Verbeken E, Lagrou K. Increasing incidence of mucormycosis in University Hospital, Belgium. Emerg Infect Dis 2010; 16 (9) 1456-1458
130 Chamilos G, Luna M, Lewis RE , et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91 (7) 986-989
131 Abidi MZ, Sohail MR, Cummins N , et al. Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies. Mycoses 2014; 57 (11) 687-698
132 Trifilio SM, Bennett CL, Yarnold PR , et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39 (7) 425-429
133 Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?. Clin Microbiol Infect 2009; 15 (Suppl. 05) 93-97
134 Auberger J, Lass-Flörl C, Aigner M, Clausen J, Gastl G, Nachbaur D. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. J Antimicrob Chemother 2012; 67 (9) 2268-2273
135 Lerolle N, Raffoux E, Socie G , et al. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. Clin Microbiol Infect 2014; 20 (11) O952-O959
136 Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350 (9) 950-952
137 Siwek GT, Dodgson KJ, de Magalhaes-Silverman M , et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39 (4) 584-587
138 Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39 (5) 743-746
139 Tacke D, Koehler P, Markiefka B, Cornely OA. Our 2014 approach to mucormycosis. Mycoses 2014; 57 (9) 519-524
140 Cornely OA, Vehreschild JJ, Rüping MJ. Current experience in treating invasive zygomycosis with posaconazole. Clin Microbiol Infect 2009; 15 (Suppl. 05) 77-81
141 Lanternier F, Sun HY, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis 2012; 54 (11) 1629-1636
142 Sun HY, Forrest G, Gupta KL , et al. Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients. Transplantation 2010; 90 (1) 85-92
143 Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994; 57 (4) 1044-1050
144 Abboud CS, Bergamasco MD, Baía CE , et al. Case report of hepatic mucormycosis after liver transplantation: successful treatment with liposomal amphotericin B followed by posaconazole sequential therapy. Transplant Proc 2012; 44 (8) 2501-2502
145 Tobón AM, Arango M, Fernández D, Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 2003; 36 (11) 1488-1491
146 Ashkenazi-Hoffnung L, Bilavsky E, Avitzur Y, Amir J. Successful treatment of cutaneous zygomycosis with intravenous amphotericin B followed by oral posaconazole in a multivisceral transplant recipient. Transplantation 2010; 90 (10) 1133-1135
147 Kulendra K, Habibi M, Butler C, Clarke P, Howard D. Use of posaconazole in the treatment of infective rhinocerebral mucormycosis. J Laryngol Otol 2010; 124 (12) 1314-1317
148 Pagano L, Cornely OA, Busca A , et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica 2013; 98 (10) e127-e130
149 Varkey JB, Perfect JR. Rare and emerging fungal pulmonary infections. Semin Respir Crit Care Med 2008; 29 (2) 121-131
150 Chen SC, Blyth CC, Sorrell TC, Slavin MA. Pneumonia and lung infections due to emerging and unusual fungal pathogens. Semin Respir Crit Care Med 2011; 32 (6) 703-716
151 Tortorano AM, Richardson M, Roilides E , et al; European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group; European Confederation of Medical Mycology. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect 2014; 20 (Suppl. 03) 27-46
152 Husain S, Muñoz P, Forrest G , et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40 (1) 89-99
153 Lackner M, de Hoog GS, Verweij PE , et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother 2012; 56 (5) 2635-2642
154 Cortez KJ, Roilides E, Quiroz-Telles F , et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21 (1) 157-197
155 Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001; 45 (7) 2151-2153
156 Vfend [package insert]. New York, NY: Pfizer, Inc.; 2014
157 Troke P, Aguirrebengoa K, Arteaga C , et al; Global Scedosporium Study Group. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52 (5) 1743-1750
158 Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002; 34 (12) 1648-1650
159 Kesson AM, Bellemore MC, O'Mara TJ, Ellis DH, Sorrell TC. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin Infect Dis 2009; 48 (9) 1257-1261
160 Koehler P, Tacke D, Cornely OA. Bone and joint infections by Mucorales, Scedosporium, Fusarium and even rarer fungi. Crit Rev Microbiol 2014; 1-14
161 Alastruey-Izquierdo A, Cuenca-Estrella M, Monzón A, Mellado E, Rodríguez-Tudela JL. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother 2008; 61 (4) 805-809
162 Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J Infect 2010; 60 (5) 331-337
163 Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20 (4) 695-704
164 Nucci M, Anaissie EJ, Queiroz-Telles F , et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003; 98 (2) 315-319
165 Lortholary O, Obenga G, Biswas P , et al; French Mycoses Study Group. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010; 54 (10) 4446-4450
166 Shobana CS, Mythili A, Homa M , et al. In vitro susceptibility of filamentous fungi from mycotic keratitis to azole drugs. J Mycol Med 2015; 25 (1) 44-49
167 Azor M, Gené J, Cano J, Guarro J. Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Antimicrob Agents Chemother 2007; 51 (4) 1500-1503
168 Wu CH, Lu PL, Hsiao HH , et al. Breakthrough Fusarium solani infection in a patient with acute myeloid leukemia receiving posaconazole prophylaxis. Ann Hematol 2014; 93 (6) 1079-1081
169 Bose P, Parekh HD, Holter JL, Greenfield RA. Disseminated fusariosis occurring in two patients despite posaconazole prophylaxis. J Clin Microbiol 2011; 49 (4) 1674-1675
170 Kontoyiannis DP, Bodey GP, Hanna H , et al. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk Lymphoma 2004; 45 (1) 139-141
171 Raad II, Hachem RY, Herbrecht R , et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42 (10) 1398-1403
172 Ho DY, Lee JD, Rosso F, Montoya JG. Treating disseminated fusariosis: amphotericin B, voriconazole or both?. Mycoses 2007; 50 (3) 227-231
173 Liu JY, Chen WT, Ko BS , et al. Combination antifungal therapy for disseminated fusariosis in immunocompromised patients: a case report and literature review. Med Mycol 2011; 49 (8) 872-878
174 Horn DL, Freifeld AG, Schuster MG, Azie NE, Franks B, Kauffman CA. Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance(®) registry. Mycoses 2014; 57 (11) 652-658
175 Herbrecht R, Kessler R, Kravanja C, Meyer MH, Waller J, Letscher-Bru V. Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant 2004; 23 (12) 1451-1454
176 Tu EY, McCartney DL, Beatty RF, Springer KL, Levy J, Edward D. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol 2007; 143 (2) 222-227
177 Pfaller MA, Diekema DJ, Gibbs DL , et al; Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48 (4) 1366-1377
178 Guinea J, Zaragoza Ó, Escribano P , et al; CANDIPOP Project, GEIH-GEMICOMED (SEIMC), and REIPI. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother 2014; 58 (3) 1529-1537
179 Howard SJ, Cerar D, Anderson MJ , et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15 (7) 1068-1076
180 Chowdhary A, Sharma C, Hagen F, Meis JF. Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiol 2014; 9 (5) 697-711
181 Steinmann J, Hamprecht A, Vehreschild MJ , et al. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother 2015; 70 (5) 1522-1526
182 van der Linden JW, Camps SM, Kampinga GA , et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 2013; 57 (4) 513-520
183 Mann PA, McNicholas PM, Chau AS , et al. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother 2009; 53 (12) 5026-5034
184 Li X, Brown N, Chau AS , et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans . J Antimicrob Chemother 2004; 53 (1) 74-80
185 Snelders E, van der Lee HA, Kuijpers J , et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5 (11) e219
186 Alanio A, Sitterlé E, Liance M , et al. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother 2011; 66 (2) 371-374
187 Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 2009; 12 (6) 141-147
188 Pfaller MA, Messer SA, Boyken L , et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008; 46 (8) 2568-2572
189 Denning DW, Park S, Lass-Florl C , et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52 (9) 1123-1129
190 Chowdhary A, Sharma C, Kathuria S, Hagen F, Meis JF. Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. J Antimicrob Chemother 2014; 69 (2) 555-557
191 Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007; 356 (14) 1481-1483
192 Mavridou E, Brüggemann RJ, Melchers WJ, Mouton JW, Verweij PE. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother 2010; 54 (2) 860-865
193 Mellado E, Garcia-Effron G, Alcázar-Fuoli L , et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007; 51 (6) 1897-1904
194 Kuipers S, Brüggemann RJ, de Sévaux RG , et al. Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole. Antimicrob Agents Chemother 2011; 55 (7) 3564-3566
195 Govender NP, Patel J, van Wyk M, Chiller TM, Lockhart SR ; Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA). Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008. Antimicrob Agents Chemother 2011; 55 (6) 2606-2611
196 Sionov E, Chang YC, Garraffo HM, Dolan MA, Ghannoum MA, Kwon-Chung KJ. Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole. Antimicrob Agents Chemother 2012; 56 (3) 1162-1169
197 Gullo FP, Rossi SA, Sardi JC, Teodoro VL, Mendes-Giannini MJ, Fusco-Almeida AM. Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment. Eur J Clin Microbiol Infect Dis 2013; 32 (11) 1377-1391
198 Guinea J, Hagen F, Peláez T , et al. Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain. Med Mycol 2010; 48 (7) 942-948
199 Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004; 48 (9) 3543-3551
200 Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47 (9) 2788-2795
201 Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44 (2) 211-220
202 Farowski F, Cornely OA, Vehreschild JJ , et al. Intracellular concentrations of posaconazole in different compartments of peripheral blood. Antimicrob Agents Chemother 2010; 54 (7) 2928-2931
203 Conte Jr JE, DeVoe C, Little E, Golden JA. Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. Antimicrob Agents Chemother 2010; 54 (9) 3609-3613
204 Conte Jr JE, Golden JA, Krishna G, McIver M, Little E, Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob Agents Chemother 2009; 53 (2) 703-707
205 Blennow O, Eliasson E, Pettersson T , et al. Posaconazole concentrations in human tissues after allogeneic stem cell transplantation. Antimicrob Agents Chemother 2014; 58 (8) 4941-4943
206 Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57 (2) 218-222
207 Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53 (3) 958-966
208 Krishna G, Ma L, Vickery D , et al. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2009; 53 (11) 4749-4752
209 Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations. Clin Pharmacokinet 2011; 50 (11) 725-734
210 Ray J, Campbell L, Rudham S, Nguyen Q, Marriott D. Posaconazole plasma concentrations in critically ill patients. Ther Drug Monit 2011; 33 (4) 387-392
211 Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 2008; 28 (10) 1223-1232
212 Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother 2012; 56 (11) 5503-5510
213 Shields RK, Clancy CJ, Vadnerkar A , et al. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother 2011; 55 (3) 1308-1311
214 Lebeaux D, Lanternier F, Elie C , et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother 2009; 53 (12) 5224-5229
215 Gross BN, Ihorst G, Jung M, Wäsch R, Engelhardt M. Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature. Pharmacotherapy 2013; 33 (10) 1117-1125
216 Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007; 27 (12) 1627-1636
217 Kraft WK, Chang PS, van Iersel ML, Waskin H, Krishna G, Kersemaekers WM. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother 2014; 58 (7) 4020-4025
218 Krishna G, Ma L, Martinho M, O'Mara E. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother 2012; 56 (8) 4196-4201
219 Jung DS, Tverdek FP, Kontoyiannis DP. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob Agents Chemother 2014; 58 (11) 6993-6995
220 Maertens J, Cornely OA, Ullmann AJ , et al. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother 2014; 58 (7) 3610-3617
221 Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 56 (6) 2806-2813
222 Howard SJ, Felton TW, Gomez-Lopez A, Hope WW. Posaconazole: the case for therapeutic drug monitoring. Ther Drug Monit 2012; 34 (1) 72-76
223 Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008; 30 (2) 167-172
224 Seyedmousavi S, Mouton JW, Verweij PE, Brüggemann RJ. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev Anti Infect Ther 2013; 11 (9) 931-941
225 Hoenigl M, Raggam RB, Salzer HJ , et al. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int J Antimicrob Agents 2012; 39 (6) 510-513
226 Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010; 88 (1) 115-119
227 Heinz WJ, Zirkel J, Kuhn A , et al. Relevance of timing for determination of posaconazole plasma concentrations. Antimicrob Agents Chemother 2011; 55 (7) 3621-3623
228 Sheppard DC, Campoli P, Duarte RF. Understanding antifungal prophylaxis with posaconazole in hematology patients: an evolving bedside to bench story. Haematologica 2014; 99 (4) 603-604
229 Andes D, Marchillo K, Conklin R , et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004; 48 (1) 137-142
230 Campoli P, Al Abdallah Q, Robitaille R , et al. Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob Agents Chemother 2011; 55 (12) 5732-5739
231 Brüggemann RJ, Alffenaar JW, Blijlevens NM , et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48 (10) 1441-1458
232 Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004; 21 (5) 645-653
233 Moton A, Krishna G, Wang Z. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. J Clin Pharm Ther 2009; 34 (3) 301-311
234 Moton A, Ma L, Krishna G, Martinho M, Seiberling M, McLeod J. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin 2009; 25 (3) 701-707
235 Billaud EM, Guillemain R, Berge M , et al. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. Med Mycol 2010; 48 (Suppl. 01) S52-S59
236 Berge M, Chevalier P, Benammar M , et al. Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis. Ther Drug Monit 2009; 31 (3) 396-399
237 Bernardo VA, Cross SJ, Crews KR , et al. Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. Ann Pharmacother 2013; 47 (7-8) 976-983
238 Jacinto PL, Chandrasekar P. Safety of posaconazole. Expert Opin Drug Saf 2013; 12 (2) 265-274
239 Raad II, Graybill JR, Bustamante AB , et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006; 42 (12) 1726-1734
240 Krishna G, Ma L, Martinho M, Preston RA, O'Mara E. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother 2012; 67 (11) 2725-2730
241 Duarte RF, López-Jiménez J, Cornely OA , et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother 2014; 58 (10) 5758-5765
242 Eiden C, Peyrière H, Tichit R , et al. Inherited long QT syndrome revealed by antifungals drug-drug interaction. J Clin Pharm Ther 2007; 32 (3) 321-324
243 Owens Jr RC, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006; 43 (12) 1603-1611
244 Zonios DI, Gea-Banacloche J, Childs R, Bennett JE. Hallucinations during voriconazole therapy. Clin Infect Dis 2008; 47 (1) e7-e10
245 Aksoy F, Akdogan E, Aydin K , et al. Voriconazole-induced neuropathy. Chemotherapy 2008; 54 (3) 224-227
246 Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46 (2) 201-211
247 Moriyama B, Henning SA, Leung J , et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses 2012; 55 (4) 290-297
248 Pakyz A, Bearman G. Adverse drug events complicate antifungal therapy for pulmonary aspergilloma. Consult Pharm 2008; 23 (10) 804-808
249 Moon WJ, Scheller EL, Suneja A , et al. Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain. Clin Infect Dis 2014; 59 (9) 1237-1245
250 Thompson III GR, Bays D, Cohen SH, Pappagianis D. Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: an assessment of currently available triazoles. Antimicrob Agents Chemother 2012; 56 (1) 563-564
251 Goyal RK, Gehris RP, Howrie D, Cogley KM, Windreich RM, Venkataramanan R. Phototoxic dermatoses in pediatric BMT patients receiving voriconazole. Pediatr Blood Cancer 2014; 61 (7) 1325-1328
252 McCarthy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007; 44 (5) e55-e56
253 Miller DD, Cowen EW, Nguyen JC, McCalmont TH, Fox LP. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010; 146 (3) 300-304
254 Williams K, Mansh M, Chin-Hong P, Singer J, Arron ST. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis 2014; 58 (7) 997-1002
255 Marriott D, Levy R, Doyle T, Ray J. Posaconazole-induced topiramate toxicity. Ann Intern Med 2009; 151 (2) 143
256 Krishna G, Moton A, Ma L, Martinho M, Seiberling M, McLeod J. Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. J Acquir Immune Defic Syndr 2009; 51 (4) 437-444
257 Brüggemann RJ, van Luin M, Colbers EP , et al. Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. J Antimicrob Chemother 2010; 65 (10) 2188-2194
258 Heinz WJ, Grau A, Ulrich A , et al. Impact of benzodiazepines on posaconazole serum concentrations. A population-based pharmacokinetic study on drug interaction. Curr Med Res Opin 2012; 28 (4) 551-557
259 Krishna G, Moton A, Ma L , et al. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther 2009; 31 (2) 286-298
260 Krishna G, Ma L, Prasad P, Moton A, Martinho M, O'Mara E. Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers. Expert Opin Drug Metab Toxicol 2012; 8 (1) 1-10
261 Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007; 27 (6) 825-834
262 Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 2007; 23 (3) 545-552
263 Kubiak DW, Koo S, Hammond SP , et al. Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants. Biol Blood Marrow Transplant 2012; 18 (9) 1462-1465
264 Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin 2013; 29 (1) 1-12
265 Hohmann C, Kang EM, Jancel T. Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations. Clin Infect Dis 2010; 50 (6) 939-940